Table 3. Self-reported β₂-agonist use in medical records versus electronic monitoringa .

Patient code b	Number of actuations measured by electronic monitor in the 24 h preceding attendance c	Self-reported β2-agonist use documented in hospital medical records
SMART B	18	Using inhaler every 20 min
SMART C	7	Using inhaler four times a day
SMART F	39	Using inhaler every 30 min
SMART Gd	42	Using multiple doses of own medicine
Standard A	13	4 actuations of salbutamol
Standard B	3	12 puffs of salbutamol
Standard C	18	3 puffs of salbutamol in 2 h
Standard D	8	6 puffs of salbutamol every 1–2 h
Standard E	30	Salbutamol 20 times per day
Standard H	86	Increasing use of salbutamol in the past 24 h
Standard Ie	25	Using salbutamol three times per day

^a4/10 and 7/12 of attendances in the Single combination inhaler as Maintenance And Reliever Therapy (SMART) and Standard groups had self-reported β₂-agonist use documented in the hospital medical records.

^bRefers to patient code on the figures displaying individual patient patterns of use.

^cNumber of budesonide/formoterol actuations for SMART and number of salbutamol actuations for Standard.

^dBefore the fourth attendance.

^eBefore the first attendance.